^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Hedera

i
Other names: Hedera | Hedera Dx | Hedera dx | Hedera DX | HEDERA DX
Related tests:
Evidence

News

4ms
Institute of Pathology at the Technical University of Munich achieves excellent results in the QuIP Proficiency test for the detection of ESR1 mutations using a Hedera Dx Liquid Biopsy test panel (Hedera Dx Press Release)
"Hedera Dx...announce that the Institute of Pathology at the Technical University of Munich (TUM) has successfully passed the QuIP proficiency test for the detection of ESR1 mutations in breast cancer patients using the Hedera Profiling 2 ctDNA Test Panel (HP2)."
Clinical data
|
Hedera Profiling 2 ctDNA test panel
1year
Hedera Dx launches blood based cancer testing that allows larger patient populations to access cancer therapies (Hedera Dx Press Release)
"Hedera Dx...has unveiled a fully streamlined solution that allows hospitals to adopt liquid biopsy testing locally for their patients with minimal efforts. The solution is a combination of laboratory reagents and a software platform...The solution is called Hedera Profiling 2 ctDNA Test Panel and it integrates easily with the existing instrument infrastructure of a hospital lab. The test is built on actionability, in other words focusing on finding a potential treatment."
Launch
|
Hedera Profiling 2 ctDNA test panel
2years
Hedera Dx hopes to Hasten liquid biopsy adoption in Europe with streamlined platform (Genomeweb)
"Swiss cancer liquid biopsy startup Hedera Dx is hoping to fill an unmet need in the cancer sequencing market, offering hospitals and community oncology providers a blood-based sequencing test and interpretation tool that can be rapidly deployed and easily kept in compliance with evolving regulatory requirements."
Commercial
2years
Hedera Dx raises €14 million in seed funding to accelerate global adoption of liquid biopsies (Hedera Dx Press Release)
"Swiss techbio company Hedera Dx...will be launching this fall a blood-based testing solution to profile cancer DNA circulating in the blood, helping patients access better treatments. To do this, the company has raised €14M in funding."
Financing • Launch